KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Revenue (2018 - 2025)

Historic Revenue for Aurinia Pharmaceuticals (AUPH) over the last 10 years, with Q3 2025 value amounting to $73.5 million.

  • Aurinia Pharmaceuticals' Revenue rose 840.63% to $73.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $265.8 million, marking a year-over-year increase of 2062.39%. This contributed to the annual value of $235.1 million for FY2024, which is 3396.9% up from last year.
  • Per Aurinia Pharmaceuticals' latest filing, its Revenue stood at $73.5 million for Q3 2025, which was up 840.63% from $70.0 million recorded in Q2 2025.
  • In the past 5 years, Aurinia Pharmaceuticals' Revenue registered a high of $73.5 million during Q3 2025, and its lowest value of $914000.0 during Q1 2021.
  • Over the past 5 years, Aurinia Pharmaceuticals' median Revenue value was $45.1 million (recorded in 2023), while the average stood at $41.9 million.
  • Its Revenue has fluctuated over the past 5 years, first surged by 5047586.21% in 2021, then plummeted by 226.61% in 2023.
  • Quarter analysis of 5 years shows Aurinia Pharmaceuticals' Revenue stood at $23.4 million in 2021, then grew by 21.5% to $28.4 million in 2022, then soared by 58.59% to $45.1 million in 2023, then soared by 32.76% to $59.9 million in 2024, then rose by 22.72% to $73.5 million in 2025.
  • Its last three reported values are $73.5 million in Q3 2025, $70.0 million for Q2 2025, and $62.5 million during Q1 2025.